Beijing Gobroad Hospital

This early-phase trial tests a new treatment called FL-33 CAR T for people with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells. The main goals are to check s…

This study is testing a new treatment called STR-P004 in 39 adults with autoimmune diseases that have come back or not responded to other treatments. The main goal is to see if it is safe and what side effects it may cause. Researchers will also look at how the drug works in the …

This study tests a new treatment using a patient's own immune cells, modified to attack lupus-causing cells, for people with severe lupus that hasn't responded to standard therapies. About 18 participants aged 3 to 65 will receive the therapy and be monitored for safety and disea…

This early-stage study tests a new cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has returned or not responded to treatment and has spread outside the bone marrow. The main goal is to check the safety of this ap…

This study tests a new treatment called CD5 CAR-T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells (or cells from a donor) that are specially trained to find and attack cancer ce…

This early-stage study tests a new treatment called CT1190B CAR-T cell therapy in 27 adults with moderate to severe lupus or systemic sclerosis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive …

This study tests a treatment called CT041, which uses a patient's own immune cells (T-cells) that are modified in a lab to target and attack stomach cancer cells. It is for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The tre…

This study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Participants will be randomly assigned to receive either standard c…

This study tests a new treatment using specially engineered immune cells (CD7 CAR T-cells) for people with T-cell cancers that have come back or not responded to standard therapy. The cells are made from the patient's own blood or from a donor. The goal is to see if this treatmen…

This study tests two different CAR T-cell therapy approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one type (CD19) follow…

This study tests a new treatment called nanobody CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer ce…

This study tests a new treatment using a patient's own immune cells, modified to attack harmful cells in three severe autoimmune diseases: lupus kidney disease, scleroderma, and Sjogren's syndrome with lung complications. About 45 adults will receive a single infusion of CD19-BCM…

This early-phase study tests a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe systemic sclerosis or Sjögren's syndrome that have not responded to sta…

This early-phase trial is testing a new treatment made from donated cord blood cells, engineered to target and destroy faulty immune cells. It is for people with severe lupus kidney disease, systemic sclerosis, or Sjogren's syndrome with lung complications. The main goal is to se…

This study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with conditions like lupus that have not responded to standard therapies. The goal is to see if this approach is…

This study tests a two-step treatment for people with a type of leukemia that has come back or not responded to standard care. First, participants receive donor immune cells (CAR T cells) that target a protein called CD19 on cancer cells, followed by a stem cell transplant from t…

This early-stage trial tests a new type of cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cancer cells. It is for people whose multiple myeloma has come back or stopped responding to treatment and has spread to tissues outside the bone marrow. The main goal i…

This early-phase study tests whether a new treatment called BiTE-EV is safe and can help adults with relapsed or hard-to-treat acute B-cell leukemia. Only 3 participants will receive the therapy every other day for 1-2 months and be followed for side effects and treatment respons…

This early-phase trial is testing a new treatment called TC-G203 for people with advanced solid tumors that have a specific marker (GPC3) and have not responded to standard therapies. The main goal is to find the safest dose and check for side effects. About 30 adults will take p…

This early-stage study tests a new treatment for adults with advanced gastrointestinal cancer that hasn't responded to standard therapies. The treatment combines a drug called XH001 with a personalized vaccine made from the patient's own tumor markers, plus immune cells trained t…